GlassScriptPhysician profile
Lorie D Gottwald
NPI 1720072275
$460,098.53
in general payments reported to CMS, 2019-2025
25 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121K · 2020: $44K · 2021: $43K · 2022: $49K · 2023: $47K · 2024: $97K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $15K · Food and Beverage: $11K · Consulting Fee: $9,070 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,936.00 |
| Travel and Lodging | $14,959.86 |
| Food and Beverage | $10,835.62 |
| Consulting Fee | $9,070.00 |
| Education | $346.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177,102.43 | 2019-2025 | |
| Janssen Biotech, INC. | $65,448.12 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $63,174.94 | 2019-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $53,234.77 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $33,790.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $23,248.45 | 2019-2025 | Dupixent |
| Genzyme Corporation | $17,015.09 | 2019-2025 | |
| Galderma Laboratories, L.P. | $12,570.72 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $8,796.18 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $2,381.55 | 2019-2025 | Bimzelx, Cimzia |
| Almirall LLC | $814.18 | 2021-2022 | |
| Pfizer INC. | $614.16 | 2021-2025 | |
| Leo Pharma INC. | $447.33 | 2019-2025 | Adbry |
| Lilly USA, LLC | $349.77 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $212.66 | 2022-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.79 | 2022-2025 | Spevigo |
| Amgen INC. | $148.49 | 2020-2024 | Otezla |
| Celgene Corporation | $138.41 | 2019 | |
| Incyte Corporation | $126.87 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.32 | 2019-2020 | |
| Smith+Nephew, INC. | $55.67 | 2025 | Grafix Pl |
| Vyne Pharmaceuticals INC. | $50.33 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $40.59 | 2019-2021 | |
| Dermira, INC. | $18.93 | 2021 | |
| Myriad Genetic Laboratories, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorie Gottwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.